Related Experiment Videos
S15261 antagonises amylin-induced impaired glucose tolerance
J Espinal1, F Lacour, S Berger
1Division des Maladies Métaboliques, Institut de Recherches Servier, Suresnes, France.
Abstract:
Amylin has been postulated to antagonise or inhibit the action of insulin in peripheral rat tissues and thus contribute to, or be responsible for, the development of insulin resistance. We have recently reported that S15261 is a compound capable of increasing insulin sensitivity in ageing insulin resistant rats. In order to assess whether S15261 had any effects on amylin induced insulin resistance we used a model where amylin causes an impairement in glucose tolerance in an acute manner, by means of an intraportal infusion of the hormone in normal rats. We report here that S15261 can antagonise this amylin-induced impaired glucose tolerance.
Insights
The compound S15261 counteracts amylin
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Background:
- Amylin is implicated in insulin resistance by antagonizing insulin action in peripheral tissues.
- The compound S15261 has previously shown potential in enhancing insulin sensitivity in aged, insulin-resistant rats.
Purpose of the Study:
- To investigate the effect of S15261 on amylin-induced insulin resistance.
- To determine if S15261 can antagonize the impairment in glucose tolerance caused by amylin.
Main Methods:
- Utilized a rat model where amylin infusion acutely impairs glucose tolerance.
- Administered S15261 to assess its impact on amylin-induced glucose intolerance.
Main Results:
- S15261 demonstrated the ability to antagonize amylin-induced impaired glucose tolerance.
- This suggests a potential therapeutic role for S15261 in conditions involving amylin-related insulin resistance.
Conclusions:
- S15261 can effectively counteract the acute glucose intolerance induced by amylin in rats.
- These findings support S15261 as a potential therapeutic agent for managing insulin resistance associated with amylin.